Every material Form 8-K Zai Lab Ltd has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Zai Lab reported third-quarter 2026 total revenue of $108.2 million, down from $116.1 million a year earlier, and a net loss of $46.1 million, or $0.04 per ordinary share, compared with $36.0 million, or $0.03, in the prior-year quarter. The company attributed the larger loss mainly to $13.6 million in inventory write-downs and said it completed a private placement with gross proceeds of about $250.0 million in October 2026.
Total revenue was $108.2 million, versus $116.1 million in Q3 2025; net product revenue rose 2% from Q2 2026.
Net loss was $46.1 million ($0.04 per share), versus $36.0 million ($0.03 per share) a year earlier, mainly due to $13.6 million in inventory write-downs.
Private placement of 11,340,000 ADSs at $22.04 each closed October 27, 2026, with net proceeds of about $241.2 million.
Cash, restricted cash and short-term investments totaled $659.7 million at September 30, 2026, down from $717.5 million at June 30, 2026.
Zai Lab agreed on October 22, 2026 to sell 11,340,000 American depositary shares to accredited investors at $22.04 per ADS in a private placement. The company expects about $250 million in proceeds before placement fees and other expenses, which it plans to use to fund pipeline development and for working capital and general corporate purposes. The new shares will add to the share count, and the company must file a resale registration statement within 15 days of closing.
Sale of 11,340,000 ADSs at $22.04 per ADS to accredited investors, announced October 22, 2026
Expected gross proceeds of about $250 million before placement agent fees and other expenses
Closing expected on or about October 27, 2026, subject to customary closing conditions
Company must file a resale registration statement within 15 days of the closing, subject to allowable delays
Zai Lab reported second-quarter 2026 total revenue of $106.3 million, down from $110.0 million a year earlier, while its net loss widened to $50.8 million from $40.7 million. The company said the higher loss was primarily due to higher licensing fees, which lifted research and development expenses to $61.8 million from $50.6 million. Cash, short-term investments and current restricted cash totaled $717.5 million at June 30, 2026, down from $761.3 million at March 31, 2026.
Total revenue was $106.3 million, compared with $110.0 million in the second quarter of 2025.
Net loss was $50.8 million, or $0.05 per ordinary share, versus a net loss of $40.7 million, or $0.04 per share, a year earlier.
Loss from operations was $76.5 million, compared with $54.9 million a year earlier; adjusted loss from operations was $60.4 million.
Cash and equivalents and related balances totaled $717.5 million at June 30, 2026, versus $761.3 million at March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Zai Lab Ltd filing is on SEC EDGAR ↗. 8-K briefs of other companies →